Volume 81, Issue 6, Pages (March 2012)

Slides:

Advertisements

Similar presentations

Accomplish Update: Fixed Dose RAAS Blocker and CCB in Prevention of Endpoints in the Treatment of Hypertension Prof. Sverre E. Kjeldsen, MD, PhD Past-President.

Advertisements

Volume 83, Issue 2, Pages (February 2013)

Reduced renal function in patients with simple renal cysts

Volume 65, Issue 3, Pages (March 2004)

Beta blockers in the management of chronic kidney disease

Urinary ammonia and long-term outcomes in chronic kidney disease

Tuberculosis and tubulointerstitial nephritis: an intriguing puzzle

No difference in bleeding risk between subcutaneous enoxaparin and heparin for thromboprophylaxis in end-stage renal disease Kevin E. Chan, Ravi I. Thadhani,

Volume 65, Issue 3, Pages (March 2004)

Volume 83, Issue 3, Pages (March 2013)

C-reactive protein and dialysis access

The risk of hospitalization and modality failure with home dialysis

Volume 57, Issue 5, Pages (May 2000)

Corrections to "Estimating the glomerular filtration rate from serum creatinine is better than from cystatin C for evaluating risk factors associated.

Volume 80, Issue 1, Pages (July 2011)

C-reactive protein and dialysis access

John P. Middleton, Patrick H. Pun Kidney International

Volume 88, Issue 2, Pages (August 2015)

Michael A. Weber, MD, George L

Better nephrology for mice—and man

Volume 77, Issue 8, Pages (April 2010)

C.Y. Hsu, J.D. Ordoñez, G.M. Chertow, D. Fan, C.E. McCulloch, A.S. Go

How to interpret the eGFR in patients with small body surface area

Volume 84, Issue 5, Pages (November 2013)

Comorbidity and confounding in end-stage renal disease

Ananda Chapagain, Hamish Dobbie, Michael Sheaff, Muhammad M. Yaqoob

Volume 82, Issue 3, Pages (August 2012)

Renal risk scores: Progress and prospects

Long-term study of mycophenolate mofetil treatment in IgA nephropathy

Volume 79, Issue 9, Pages (May 2011)

Volume 87, Issue 2, Pages (February 2015)

Volume 85, Issue 6, Pages (June 2014)

Correction to "Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate.

U-shaped effect of eGFR and mortality

Volume 76, Issue 10, Pages (November 2009)

Volume 83, Issue 4, Pages (April 2013)

Volume 67, Pages S48-S51 (January 2005)

Volume 82, Issue 3, Pages (August 2012)

Aggressive blood pressure reduction and renin–angiotensin system blockade in chronic kidney disease: time for re-evaluation? Pantelis A. Sarafidis, Luis.

Modulating kidney transplant interstitial fibrosis and tubular atrophy: is the RAAS an important target? Hatem Amer, Matthew D. Griffin Kidney International

Volume 85, Issue 3, Pages (March 2014)

Volume 81, Issue 6, Pages (March 2012)

Volume 76, Issue 3, Pages (August 2009)

Atherosclerotic renovascular disease among hypertensive adults

Volume 82, Issue 7, Pages (October 2012)

Volume 85, Issue 5, Pages (May 2014)

Methods for guideline development

Volume 84, Issue 5, Pages (November 2013)

Racial disparities in access to transplantation: a tough nut to crack

Volume 76, Issue 8, Pages (October 2009)

Reduced renal function in patients with simple renal cysts

Volume 80, Issue 6, Pages (September 2011)

Volume 85, Issue 5, Pages (May 2014)

Volume 84, Issue 4, Pages (October 2013)

Volume 80, Issue 3, Pages (August 2011)

Prehypertension: is it relevant for nephrologists?

Cardiovascular risk assessment in kidney transplantation

Volume 77, Issue 12, Pages (June 2010)

Racial differences in survival of patients on dialysis

ACE inhibition is effective and renoprotective in hypertensive nephrosclerosis: The African American Study of Kidney Disease and Hypertension (AASK) trial

Volume 74, Issue 9, Pages (November 2008)

Carmine Zoccali, Francesca Mallamaci Kidney International

Volume 76, Issue 6, Pages (September 2009)

Volume 83, Issue 3, Pages (March 2013)

Volume 80, Issue 10, Pages (November 2011)

Volume 81, Issue 7, Pages (April 2012)

Michael R. Lattanzio, Matthew R. Weir Kidney International

Adiponectin: good, bad, or just plain ugly?

Volume 73, Issue 11, Pages (June 2008)

Volume 86, Issue 2, Pages (August 2014)

Presentation transcript:

Volume 81, Issue 6, Pages 568-576 (March 2012) Renal outcomes in hypertensive Black patients at high cardiovascular risk Matthew R. Weir, George L. Bakris, Michael A. Weber, Bjorn Dahlof, Richard B. Devereux, Sverre E. Kjeldsen, Bertram Pitt, Jackson T. Wright, Roxzana Y. Kelly, Tsushung A. Hua, R Allen Hester, Eric Velazquez, Kenneth A. Jamerson Kidney International Volume 81, Issue 6, Pages 568-576 (March 2012) DOI: 10.1038/ki.2011.417 Copyright © 2012 International Society of Nephrology Terms and Conditions

Figure 1 Kaplan–Meier curves for the composite end point of more than 50% increase in serum creatinine or adjudicated renal end point—by self-described ethnicity (US patients). Kidney International 2012 81, 568-576DOI: (10.1038/ki.2011.417) Copyright © 2012 International Society of Nephrology Terms and Conditions

Figure 2 Mean change from baseline in estimated glomerular filtration rate (eGFR) by race/ethnicity and treatment groups (US patients); slope difference calculated from baseline between B+A and B+H in Blacks (P<0.02) and non-Blacks (P<0.0001). B+A, benazepril and amlodipine; B+H, benazepril and hydrochlorothiazide; Blk, Black; CI, 95% confidence interval. Kidney International 2012 81, 568-576DOI: (10.1038/ki.2011.417) Copyright © 2012 International Society of Nephrology Terms and Conditions

Figure 3 Mean change from month 3 in estimated glomerular filtration rate (eGFR)—by race/ethnicity and treatment group (US patients); slope difference between B+A and B+H calculated from month 3: Blacks (P=0.785) and non-Blacks (P=0.022). B+A, benazepril and amlodipine; B+H, benazepril and hydrochlorothiazide; Blk, Black; CI, 95% confidence interval. Kidney International 2012 81, 568-576DOI: (10.1038/ki.2011.417) Copyright © 2012 International Society of Nephrology Terms and Conditions

Figure 4 Kaplan–Meier curves for the composite end point of >50% increase from month 3 in serum creatinine or adjudicated renal end point after month 3—by race/ethnicity and treatment group (US patients). B+A, benazepril and amlodipine; B+H, benazepril and hydrochlorothiazide; Blk, Black. Kidney International 2012 81, 568-576DOI: (10.1038/ki.2011.417) Copyright © 2012 International Society of Nephrology Terms and Conditions

Figure 5 Mean change from month 3 in estimated glomerular filtration rate (eGFR)—by treatment group (US patients); slope difference calculated from month 3 between B+A and B+H is P=0.035. B+A, benazepril and amlodipine; B+H, benazepril and hydrochlorothiazide; Blk, Black; CI, 95% confidence interval. Kidney International 2012 81, 568-576DOI: (10.1038/ki.2011.417) Copyright © 2012 International Society of Nephrology Terms and Conditions